Novan to Report Third Quarter 2022 Financial Results on November 14, 2022

Rhea-AI Summary

Novan, Inc. (Nasdaq: NOVN) will report its Q3 2022 financial results on November 14, 2022, at 8:30 a.m. ET. CEO Paula Brown Stafford will lead a conference call to discuss these results. The call will be accessible to investors and interested participants through a dedicated phone line and live webcast, which will also be archived for 90 days. Novan focuses on developing innovative therapies for skin diseases, including its lead product candidate, SB206 (berdazimer gel), for viral skin infections. The recent acquisition of EPI Health enhances Novan's commercial infrastructure.

Positive

• Completed acquisition of EPI Health, enhancing commercial infrastructure.
• Developing SB206 for viral skin infections, addressing unmet medical needs.

Negative

• None.

DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2022 financial results on Monday, November 14^th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com, and will be archived for 90 days.

About Novan

Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with current emphasis on molluscum contagiosum.

Novan recently completed the acquisition of EPI Health. EPI Health equips the company with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams. Following the acquisition, the company employs approximately 100 staff, including sales personnel currently covering 42 territories, and promotes products for plaque psoriasis, rosacea, acne and dermatoses. Novan also has a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL^™, to generate new treatments for multiple indications.

INVESTOR AND MEDIA CONTACT:

Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com

 

FAQ

When will Novan report its Q3 2022 financial results?

Novan will report its Q3 2022 financial results on November 14, 2022.

Who will lead the conference call for Novan's financial results?

The conference call will be led by CEO Paula Brown Stafford.

What is Novan's main focus as a company?

Novan focuses on researching, developing, and commercializing innovative therapeutic products for skin diseases.

What product is Novan developing for viral skin infections?

Novan is developing SB206 (berdazimer gel) for the treatment of viral skin infections.

What is the significance of EPI Health's acquisition for Novan?

The acquisition of EPI Health provides Novan with a robust commercial infrastructure, improving its market access and sales capabilities.